Impact Factor Collection
Endocrine-Related Cancer’s 2021 Journal Impact FactorTM has risen to 5.900, its highest value in the last decade. The journal now ranks 35 out of 146 journals in the ‘Endocrinology and Metabolism’ category of the latest Journal Citation ReportsTM, placing it in the top quartile of journals. Endocrine-Related Cancer was also ranked 72 out of 245 in the ‘Oncology’ category.
This increase in the Impact Factor is all thanks to the high quality of authors’ published articles, the dedication and commitment of the Editorial Board and reviewers, and the continued support of all our readers.
Explore the following collection of the top-cited research articles and reviews from 2021.
2021’S TOP CITED RESEARCH:
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
Esben Andreas Carlsen et al.
Antitumor effects of anlotinib in thyroid cancer
Xianhui Ruan et al.
French Endocrine Society Guidance on endocrine side effects of immunotherapy
F Castinetti et al.
Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia
Florian Bösch et al.
Neuroendocrine differentiation of prostate cancer leads to PSMA suppression
Martin K Bakht et al.
Thyroxine promotes lung cancer growth in an orthotopic mouse model
S Latteyer et al.
Radioactive iodine in differentiated thyroid cancer: a national database perspective
Ryan K Orosco et al.
2021’S TOP CITED REVIEWS:
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Neil Portman et al.
The NF-KB pathway and endocrine therapy resistance in breast cancer
Phungern Khongthong et al.
Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives
Lucieli Ceolin et al.
Otubain 1: a non-canonical deubiquitinase with an emerging role in cancer
Matthew Saldana et al.
The epigenetic and transcriptional landscape of neuroendocrine prostate cancer
Alastair Davies et al.
Redifferentiation of radioiodine-refractory thyroid cancers
Camille Buffet et al.
PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Halfdan Sorbye et al.